ScholarIQanswers from OpenAlex & ORCID
Nadia Harbeck
ResearcherPublications, citations & collaboration network
Nadia Harbeck is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Nadia Harbeck have?
ScholarIQindexed works
Nadia Harbeck has 2,055 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Nadia Harbeck have?
ScholarIQcitation count
Nadia Harbeck has 86,743 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Nadia Harbeck?
ScholarIQh-index
Nadia Harbeck has an h-index of 133 in OpenAlex.
What is the i10-index of Nadia Harbeck?
ScholarIQi10-index
Nadia Harbeck has an i10-index of 624 in OpenAlex.
What is the ORCID of Nadia Harbeck?
ScholarIQorcid
The ORCID for Nadia Harbeck is on the source record.
What is the OpenAlex record for Nadia Harbeck?
ScholarIQopenalex
The OpenAlex for Nadia Harbeck is on the source record.
What are the most-cited papers on Nadia Harbeck?
ScholarIQmost cited works
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortés, Lajos Pusztai, Heather L. McArthur, Sherko Kümmel, Jonas Bergh, Carsten Denkert, Yeon Hee Park, Rina Hui, Nadia Harbeck, Masato Takahashi, Theodoros Foukakis, Peter A. Fasching, Fátima Cardoso, Michael Untch, Liyi Jia, Vassiliki Karantza, Jing Zhao, Gursel Aktan, Rebecca Dent, Joyce O’Shaughnessy
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
Shanu Modi, William Jacot, Toshinari Yamashita, Joohyuk Sohn, María Vidal, Eriko Tokunaga, Junji Tsurutani, Naoto T. Ueno, Aleix Prat, Yee Soo Chae, Keun Seok Lee, Naoki Niikura, Yeon Hee Park, Binghe Xu, Xiaojia Wang, Miguel Gil‐Gil, Wěi Li, Jean‐Yves Pierga, Seock‐Ah Im, Halle C. F. Moore, Hope S. Rugo, Rinat Yerushalmi, Flora Zagouri, Andrea Gombos, Sung‐Bae Kim, Qiang Liu, Ting Luo, Cristina Saura, Peter Schmid, Tao Sun, Dhiraj Gambhire, Lotus Yung, Yibin Wang, Jasmeet Singh, Patrik Vitazka, Gerold Meinhardt, Nadia Harbeck, David Cameron
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso, A. Costa, Elżbieta Senkus, Matti Aapro, Fabrice André, Carlos H. Barrios, Jonas Bergh, G.S. Bhattacharyya, Laura Biganzoli, Maria João Cardoso, L. Carey, D. Corneliussen-James, Giuseppe Curigliano, Véronique Dièras, N. El Saghir, Alexandru Eniu, Lesley Fallowfield, D. Fenech, Prudence A. Francis, Karen A. Gelmon, Alessandra Gennari, Nadia Harbeck, Clifford A. Hudis, Bella Kaufman, Ian E. Krop, Musa Mayer, Hanneke Meijer, Shirley Mertz, Shinji Ohno, Olivia Pagani, Efthymios Papadopoulos, Fedro A. Peccatori, Frédérique Penault‐Llorca, Martine Piccart, Jean‐Yves Pierga, Hope S. Rugo, Lillie D. Shockney, George W. Sledge, Sandra M. Swain, Christoph Thomssen, Andrew Tutt, Daniel Vorobiof, Binghe Xu, Larry Norton, Eric P. Winer
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial
Ian Smith, Marion Procter, Richard D. Gelber, Sébastien Guillaume, A. Feyereislova, Mitch Dowsett, Aron Goldhirsch, Michael Untch, Gabriella Mariani, José Baselga, Manfred Kaufmann, David Cameron, Richard H. Bell, Jonas Bergh, Robert L. Coleman, Andrew Wardley, Nadia Harbeck, R.I. Lopez, Peter Mallmann, Karen A. Gelmon, Nicholas Wilcken, Erik Wist, Pedro Sánchez‐Rovira, Martine Piccart
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
Alessandra Gennari, Fabrice André, Carlos H. Barrios, Javier Cortés, Evandro de Azambuja, A. DeMichele, Rebecca Dent, Deborah Fenlon, Joseph Gligorov, Sara A. Hurvitz, Seock‐Ah Im, David Krug, Wolfgang G. Kunz, Sherene Loi, Frédérique Penault‐Llorca, Jens Ricke, Mark E. Robson, Hope S. Rugo, Cristina Saura, Peter Schmid, Christian F. Singer, Tanja Španić, Sara M. Tolaney, Nicholas C. Turner, Giuseppe Curigliano, Sibylle Loibl, Shani Paluch–Shimon, Nadia Harbeck